Area of Current Research Interests
Signalling pathways in cancer and normal cells; insulin signalling and its defects in type II diabetes; mechanisms of insulin action and of glucose uptake and resistance; insulin secretion and its control. Mitochondrial metabolism, its regulation, control and functions of intracellular and intramitochondrial calcium.
Resigned fellowship 30.9.90 on appointment as Head of Biochemical Pharmacology, Syntex Research Centre, Heriot-Watt University, Edinburgh.
Awarded DSc, University of Bristol, 1992.
Visiting Professor, University of Sunderland, 1994.
Appointed Head of Diabetes Biology Department, Novo Nordisk, A/S, Denmark, from 1.11.95.
Made Director of Diabetes Discovery, 1996.
Elected a Member of the Institute, 1996.
Director of Target Cell Biology, Novo Nordisk, 1998.
Vice President, Target Cell Biology, Novo Nordisk, 2000.
Appointed Vice President for Discovery Research UK, OSI Pharmaceuticals from 1.6.02.
Vice President for Research, Prosidion from 1.12.04.
Chief Scientific Officer (from 1.12.04) and Senior Vice President for Research (from 1.7.07) at (OSI) Prodidion until 31.12.08.
Co-founded McC+R&D Consulting Ltd with Dr C Reynet, December 2009.